Publikationen

2024
Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists

Popović L, Wintgens J P, Wu Y, Brankatschk B, Menninger S, Degenhart C, Jensen N, Wichert S P, Klebl B, Rossner M J and Wehr M C. iScience. 2024; doi: 10.1016/j.isci.2024.108839

Pyrrolopyrimidine based CSF1R inhibitors: Attempted departure from Flatland

Bjornstad F, Havik S, Aarhus T I, Mahdi I, Unger A, Habenberger P, Degenhart C, Eickhoff J, Klebl B M, Sundby E and Hoff B H. Eur J Med Chem. 2024; 265 116053. doi: 10.1016/j.ejmech.2023.116053

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA

Teuber A, Schulz T, Fletcher B S, Gontla R, Muhlenberg T, Zischinsky M L, Niggenaber J, Weisner J, Kleinbolting S B, Lategahn J, Sievers S, Muller M P, Bauer S and Rauh D. Nat Commun. 2024; 15 (1): 63. doi: 10.1038/s41467-023-44376-8

2015
Selective inhibitors of the FK506-binding protein 51 by induced fit

Gaali S, Kirschner A, Cuboni S, Hartmann J, Kozany C, Balsevich G, Namendorf C, Fernandez-Vizarra P, Sippel C, Zannas A S, Draenert R, Binder E B, Almeida O F, Ruhter G, Uhr M, Schmidt M V, Touma C, Bracher A, Hausch F. Nat Chem Biol. 2015; 11 (1): 33-37. doi: 10.1038/nchembio.1699

Design, synthesis and decoration of molecular scaffolds for exploitation in the production of alkaloid-like libraris

Craven P, Aimon A, Dow M, Fleury-Bregeot N, Guilleux R, Morgentin R, Roche D, Kalliokoski T, Foster R, Marsden S P, Nelson A. Bioorg Med Chem. 2015; 23 (11): 2629-2635. doi: 10.1016/j.bmc.2014.12.048

Medicinal Chemists of the 21st Century – Who Are We and Where to Go?

Nussbaumer P. ChemMedChem. 2015; 10 (7): 1133-1139. doi: 10.1002/cmdc.201500133

Expansion of Chemical Space for Collaborative Lead Generation and Drug Discovery: The European Lead Factory Perspective

Karawajczyk A, Giordanetto F, Benningshof J, Hamza D, Kalliokoski T, Pouwer K, Morgentin R, Nelson A, Muller G, Piechot A, Tzalis D. Drug Discov Today. 2015; 20 (11): 1310-1316. doi: 10.1016/j.drudis.2015.09.009

Professional translational research: a new hybrid paradigm in early drug discovery

Nussbaumer P, Klebl B. Future Med Chem. 2015; 7 (14): 1879-1889. doi: 10.4155/fmc.15.124

Price-Focused Analysis of Commercially Available Building Blocks for Combinatorial Library Synthesis

Kalliokoski T. ACS Comb Sci. 2015; 17 (10): 600-607. doi: 10.1021/acscombsci.5b00063

Protein-protein interactions as drug targets

Skwarczynska M, Ottmann C. Future Med Chem. 2015; 7 (16): 2195-2219. doi: 10.4155/fmc.15.138

Aminomethylhydroxylation of alkenes: Exploitation in the synthesis of scaffolds for small molecule libraries

Colomer I, Adeniji O, Burslem G M, Craven P, Rasmussen M O, Willaume A, Kalliokoski T, Foster R, Marsden S P, Nelson A. Bioorg Med Chem. 2015; 23 (11): 2736-2740. doi: 10.1016/j.bmc.2015.01.058

A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations

Hutterer C, Eickhoff J, Milbradt J, Korn K, Zeittrager I, Bahsi H, Wagner S, Zischinsky G, Wolf A, Degenhart C, Unger A, Baumann M, Klebl B, Marschall M. Antimicrob Agents Chemother. 2015; 59 (4): 2062-2071. doi: 10.1128/AAC.04534-14